{
    "clinical_study": {
        "@rank": "119281", 
        "arm_group": [
            {
                "arm_group_label": "Dilatrend SR capsule 32mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Dilatrend IR tablet 25mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetic characteristics and safety of\n      dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects."
        }, 
        "brief_title": "Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Essential Hypertension", 
            "Chronic Stable Angina", 
            "Congestive Heart Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hypertension", 
                "Angina Pectoris"
            ]
        }, 
        "detailed_description": {
            "textblock": "Healthy male subjects are administrated multiple-dose over the period I and II (Crossover)\n      of dilatrend SR capsule 32mg and dilatrend tablet 25mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Between 20 aged and 35aged in healthy male\n\n          -  Body Weight more than 50kg, and within 20% of ideal body weight(IBW).\n\n               -  IBW(kg) = {height(cm)-100}*0.9\n\n          -  Have not any congenital  or chronic disease and medical symptoms.\n\n          -  Suitable results of inspections(laboratory test, ECG, etc) within 21 days before IP\n             administration.\n\n          -  Agreement with written informed consent\n\n        Exclusion Criteria:\n\n          -  Subject has hypersensitivity reaction or clinically significant history about\n             carvedilol or investigator drug.\n\n          -  Clinically significant cardiovascular system, respiratory system, liver, kidney,\n             endocrine system, gastrointestinal system, central nervous system, blood tumor,\n             mental disease, skin disease, otorhinolaryngologic diseases and so on.\n\n          -  Hypotension(SBP < 105mmHg or DBP < 65mmHg),  Hypertension(SBP > 150mmHg or DBP >\n             100mmHg)\n\n          -  Heart rate < 50times/minute\n\n          -  Active liver disease or AST, ALT > 1.5*upper limit of normal range\n\n          -  Creatinine clearance < 80mL/min\n\n          -  Subject has a disease affecting drug's ADME or gastrointestinal surgery.\n\n          -  Subject with symptoms of injured or acute disease within 28days before the first IP\n             administration.\n\n          -  Subject has a history of drug abuse or a positive reaction for drug abuse at the\n             screening test for urine.\n\n          -  Taking ETC medicine including oriental medicine within 14days before the first IP\n             administration or Taking OTC medicine within 7days\n\n          -  Subject takes an abnormal meal which affect the ADME of drug.\n\n          -  Previously participate in other trial within 90days.\n\n          -  Previously make whole blood donation within 60days or component blood donation within\n             30days before the first IP administration.\n\n          -  Continued to be taking caffeine(caffeine > 5cup/day), drinking(alcohol > 21unit/week,\n             1unit = 10g = 12.5mL of pure alcohol) or during clinical trials can not be drunk or\n             severe heavy smoker(cigarette > 10cigarettes/day).\n\n          -  Subject with positive reaction about serum test(HBsAg, HCV Ab, HIV Ag/Ab, VDRL)\n\n          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,\n             glucose-galactose malabsorption.\n\n          -  An impossible one who participates in clinical trial by investigator's decision\n             including for reason of laboratory test result."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819870", 
            "org_study_id": "125HPS12006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dilatrend SR capsule 32mg", 
                "description": "1 capsule, oral, once daily, 7days\nover the period I&II(crossover)", 
                "intervention_name": "Dilatrend SR capsule 32mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dilatrend IR tablet 25mg", 
                "description": "1 tablet, oral, once daily, 7days\nover the period I&II(crossover)", 
                "intervention_name": "Dilatrend IR tablet 25mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carvedilol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carvedilol", 
            "Dilatrend SR capsule", 
            "Dilatrend Tablet", 
            "Pharmacokinetics", 
            "Healthy male subjects"
        ], 
        "lastchanged_date": "March 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of", 
                    "state": "eok-dong 2(i)-ga Jung-gu", 
                    "zip": "700-721"
                }, 
                "name": "Kyungpook National University Hospital Clinical Trial Center"
            }, 
            "status": "Completed"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects", 
        "overall_contact": {
            "email": "yry@knu.ac.kr", 
            "last_name": "Young-Ran Yoon", 
            "phone": "053-420-4950"
        }, 
        "overall_official": {
            "affiliation": "Kyungpook National University Hospital Clinical Trial Center", 
            "last_name": "Young-Ran Yoon", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 48 hours sample) determined using the linear trapezoidal rule", 
            "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCtau", 
            "safety_issue": "No", 
            "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUCinf: Area Under the Concentration time curve with the last concentration extrapolated based on the elimination rate constant Kel", 
                "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCinf", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
            }, 
            {
                "description": "Css,max : Maximum drug concentration in plasma determined directly from individual concentration-time data", 
                "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,max", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
            }, 
            {
                "description": "Css,min : Minimum drug concentration in plasma determined directly from individual concentration-time data", 
                "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,min", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
            }, 
            {
                "description": "Tss,max  : Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles", 
                "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Tss,max", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
            }, 
            {
                "description": "t\u00bd  : Observed terminal elimination half-life", 
                "measure": "In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg t\u00bd", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post\u2010dose (on last day of each period)"
            }, 
            {
                "description": "Evaluated safety parameters included: physical examination, vital sign, laboratory test, ECG\nadverse event monitoring", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From 1day to 37 days"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}